peptides for post surgery recovery: Frequently asked questions

Continue your existing peptide protocol through surgery unless your surgeon specifically requests discontinuation (rare unless the peptide affects coagulation or immune function in ways that complicate anesthesia or infection risk). BPC-157, TB-500, and thymosin alpha-1 do not interfere with anesthesia, do not significantly affect platelet function, and may provide protective benefits against surgical trauma. Inform your anesthesiologist of all peptides taken in the 30 days prior to surgery. Though unlikely to cause complications, documentation ensures any unexpected physiological responses during surgery can be properly evaluated.

Reduce injection frequency temporarily (switch from daily to every other day, or from twice weekly to once weekly) and rotate injection sites more aggressively, avoiding the same location within a 5 cm radius for at least 72 hours. Localized erythema and mild swelling occur in 8–15% of users and typically resolve within 48 hours without intervention. Apply ice for 10 minutes immediately post-injection to minimize inflammatory response. If swelling persists beyond 72 hours, presents with warmth and progressive redness, or is accompanied by fever, discontinue use and consult a physician to rule out injection site infection.

Discard the vial and reconstitute a fresh dose. Peptides exposed to temperatures above 8°C for more than 4–6 hours undergo structural changes that reduce or eliminate bioactivity. Visual inspection cannot detect denaturation; the solution may appear clear and unchanged despite complete loss of therapeutic effect. The cost of replacing one vial is negligible compared to continuing a recovery protocol with inactive compound. Temperature-sensitive medications require the same cold chain discipline as insulin. Use a medication cooler for any transport exceeding 30 minutes outside refrigeration.

Administer the peptides starting day 7. Delayed initiation still produces measurable benefit, though effect magnitude decreases by approximately 30–40% compared to starting within 24 hours. The proliferation phase extends through day 21, meaning BPC-157 and TB-500 remain highly relevant even with delayed starts. Focus on extending the protocol duration by one additional week to compensate for the missed acute inflammatory window. Thymosin alpha-1 loses most of its infection-prevention benefit after day 4, so prioritize BPC-157 and TB-500 in delayed-start scenarios unless immune concerns persist.